What changed in this filing

/stocks — the workspaceLOADING

Item 1. Financial Statements

2026-05-13 compared with 2025-11-13 · 200 added, 473 removed, 288 unchanged (70% of the section changed)

3 unchanged sentences

(in thousands, except par value and share amounts)

September 30, 2025 December 31, 2024

March 31, 2026 December 31, 2025

Current Assets:

Cash and cash equivalents $ 7,264 $ 3,468

Accounts receivable, net 1,822 513

Accounts receivable and contract assets, net 1,991 2,787

Inventories, net 4,645 4,971

Prepaids and deposits 334 178

Prepaid expenses and other current assets 574 194

Total current assets 14,474 11,420

Property and equipment, net 105 123

Operating lease right of use assets, net 2,242 1,964

Operating lease right-of-use asset, net 447 2,175

Intangible assets, net 1,592 1,572

Other assets, net 128 186

Other assets 104 128

Total assets 16,722 15,418

6 unchanged sentences

Operating lease liability — short term 90 320

Warrants- short term - 10,131

Total current liabilities 1,908 1,817

3 unchanged sentences

Total liabilities 2,288 3,928

Commitments and Contingencies

Commitments and Contingencies (Note 13)

Stockholders' Equity

1 unchanged sentence

par value $ 0.0001 per share;

12,707 shares issued and outstanding at September 30, 2025, and December 31, 2024 - -

11,707 and 12,707 shares issued and outstanding at March 31, 2026, and December 31, 2025, respectively.

Common stock - 200,000,000 authorized;

par value $ 0.0001 per share;

51,497,710 and 47,101,631 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively $ 5 $ 5

Series A convertible preferred stocks - 10,000 authorized, par value $ 0.0001 per share;

8,207 shares issued and outstanding at September 30, 2025 and December 31, 2024 - -

Series B convertible preferred stocks - 4,500 authorized, par value $ 0.0001 per share, 4,500 and 0 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively - -

55,506,692 and 51,733,217 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively 5 5

Series A convertible preferred stock - 10,000 authorized, par value $ 0.0001 per share;

8,107 and 8,207 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively - -

Series B convertible preferred stock - 4,500 authorized, par value $ 0.0001 per share, 3,600 and 4,500 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively - -

Additional paid-in capital 135,537 127,804

6 unchanged sentences

(in thousands, except share and per share amounts)

Three Months Ended September 30, Nine Months Ended September 30,

2025 2024 2025 2024

Three Months Ended March 31,

Product sales $ 883 $ 309

Managed services 242 - 1,241 -

Technology enabled services 228 456

Total revenues, gross 2,022 593 3,799 3,642

Sales returns and allowances ( 531 ) - ( 531 ) -

Total revenues, net 1,491 593 3,268 3,642

Total revenues 1,111 765

Cost of revenues 420 170

7 unchanged sentences

Interest income 1 2

Change in fair value of warranty liabilities - 5,600 3,158 12,517

Other ( 14 ) ( 5 ) ( 14 ) ( 15 )

Change in fair value of warrant liabilities - 4,029

Gain on lease termination 227 -

Total other income (expense), net 229 4,031

1 unchanged sentence

Convertible preferred stock dividends ( 249 ) ( 164 )

Net (loss) income attributable to common stockholders $ ( 2,937 ) $ 1,673 $ ( 6,883 ) $ 705

Net (loss) income per basic and diluted share of Common Stock $ ( 0.06 ) $ 0.04 $ ( 0.14 ) $ 0.02

Weighted average common shares used to compute net loss per basic and diluted shares of Common Stock 51,096,292 45,861,208 49,998,057 45,067,793

Net loss attributable to common stockholders $ ( 4,789 ) $ ( 55 )

Net loss per basic and diluted share $ ( 0.09 ) $ -

Weighted average common shares — basic and diluted 54,001,602 48,396,271

Comprehensive (loss) income:

1 unchanged sentence

Comprehensive (loss) income:

( 4,540 ) 109

The accompanying notes are an integral part of these financial statements.

2 unchanged sentences

(in thousands, except share amounts)

Three Months Ended September 30, 2025

Series A Convertible Series B Convertible Additional Total

Common Stock Preferred Stock Preferred Stock Paid-in Accumulated Stockholders’

Common Stock Preferred Stock Additional

Series A Convertible Series B Convertible Paid-in Accumulated Stockholders'

Shares Amount Shares Amount Shares Amount Capital Deficit Equity

Balance at July 1, 2025 50,728,535 $ 5 8,207 $ - - $ - $ $ 120,783 $ ( 109,027 ) $ 11,761

Share-based compensation expense - - - - - - 638 - 638

Dividends on convertible preferred stock 153,409 - - - - - 164 ( 164 ) -

Common Stock issued upon vesting of restricted stock units 615,766 - - - - - - - -

Series B Convertible Preferred Stock issuance - - - - 4,500 - 4,500 - 4,500

Reclassification of warrant liability due to warrant amendment - - - - - - - - -

Net loss for the period - - - - - - - ( 2,773 ) ( 2,773 )

Balance at September 30, 2025 51,497,710 5 8,207 $ - 4,500 $ - $ 126,085 $ ( 111,964 ) $ 14,126

Nine months Ended September 30, 2025

Balance at January 1, 2025 47,101,631 $ 5 8,207 $ - - $ - $ 105,326 $ ( 105,081 ) $ 250

Balance at December 31, 2025 51,733,217 $ 5 8,207 $ - 4,500 $ - $ 127,804 $ ( 116,319 ) $ 11,490

Share-based compensation expense - - - - - - 2,384 - 2,384

1 unchanged sentence

Common Stock issued upon vesting of restricted stock units 72,888 - - - - - - - -

Series B Convertible Preferred Stock issuance - - - - 4,500 - 4,500 - 4,500

Common Stock issued with Private Placement 3,216,666 - - - - - 543 - 543

Reclassification of warrant liability due to warrant amendment - - - - - - 12,151 - 12,151

Net loss for the period - - - - - - - ( 6,391 ) ( 6,391 )

Balance at September 30, 2025 51,497,710 $ 5 8,207 $ - 4,500 $ - $ 126,085 $ ( 111,964 ) $ 14,126

Common Stock issued upon conversion of preferred stock 668,965 - ( 100 ) - ( 900 ) - - - -

Common Stock and pre-funded warrants issued with Private Placement 2,500,000 - - - - - 5,000 - 5,000

Common Stock issued upon warrant exercise 68,966 - - - - - 100 - 100

Net loss - - - - - - - ( 4,540 ) ( 4,540 )

Balance at March 31, 2026 55,506,692 $ 5 8,107 $ - 3,600 $ - $ 135,537 $ ( 121,108 ) $ 14,434

The accompanying notes are an integral part of these financial statements.

2 unchanged sentences

(in thousands, except share amounts)

Three Months Ended September 30, 2024

Series A Convertible Series B Convertible Additional Total

Common Stock Preferred Stock Preferred Stock Paid-in Accumulated Stockholders’

Common Stock Preferred Stock Additional

Series A Convertible Series B Convertible Paid-in Accumulated Stockholders'

Shares Amount Shares Amount Shares Amount Capital Deficit Equity

Balance at July 1, 2024 45,793,112 $ 4 8,207 $ - - $ - $ 102,793 $ ( 98,956 ) $ 3,841

Share-based compensation expense - - - - - - 896 - 896

Dividends on convertible preferred stock - - - - - - ( 4 ) ( 317 ) ( 321 )

Common Stock issued upon convertible preferred stock exercising conversion rights - - - - - - - - -

Common Stock issued upon vesting of restricted stock units 76,278 - - - - - - - -

Net income for the period - - - - - - - 1,990 1,990

Balance at September 30, 2024 45,869,390 $ 4 8,207 $ - - $ - $ 103,685 $ ( 97,283 ) $ 6,406

Nine months Ended September 30, 2024

Balance at January 1, 2024 43,855,503 $ 4 9,898 $ - - $ - $ 101,147 $ ( 97,988 ) $ 3,163

Common Stock issued upon exercise of stock options 232,081 - - - - - 588 - 588

Balance at December 31, 2024 47,101,631 $ 5 8,207 $ - - $ - $ 105,326 $ ( 105,081 ) $ 250

Share-based compensation expense - - - - - - 1,665 - 1,665

Dividends on convertible preferred stock 113,205 - - - - - 164 ( 164 ) -

Common Stock issued upon convertible preferred stock exercising conversion rights 1,391,183 - ( 1,691 ) - - - - - -

Common Stock issued upon vesting of restricted stock units 63,199 - - - - - - - -

Common Stock issued — Private Placement 3,216,666 - - - - - 543 - 543

Net income for the period - - - - - - - 109 109

Balance at September 30, 2024 45,869,390 $ 4 8,207 $ - - $ - $ 103,685 $ ( 97,283 ) $ 6,406

Balance at March 31, 2025 50,494,701 $ 5 8,207 $ - - $ - $ 107,698 $ ( 105,136 ) $ 2,567

The accompanying notes are an integral part of these financial statements.

2 unchanged sentences

(in thousands)

Nine Months ended September 30,

Three Months Ended March 31,

Cash Flows From Operating Activities:

Net (loss) income $ ( 4,540 ) $ 109

Adjustments to reconcile net loss to net cash used in operating activities:

Adjustments to reconcile net income (loss) to net cash used in operating activities:

Depreciation and amortization 56 155

Loss on disposition of assets 9 -

Share-based compensation 2,384 1,665

Warranty provision 4 2

Gain on lease termination ( 227 ) -

Change in fair value of warrant liabilities - ( 4,029 )

Non-cash lease expense 54 74

Provision for doubtful accounts 35 ( 89 )

(Reversal) / Provision for credit losses ( 1 ) 37

Inventory obsolescence reserve - 18

Changes in assets and liabilities:

Accounts receivable ( 1,344 ) 2,337

Accounts receivable and contract assets 797 ( 184 )

Inventories 326 71

1 unchanged sentence

Accounts payable 167 ( 115 )

Operating lease liability 295 ( 99 )

Operating lease liabilities ( 57 ) ( 74 )

Customer deposits ( 11 ) -

Accrued liabilities and other 122 ( 272 )

Warranty settlement ( 13 ) ( 42 )

Warranty settlements ( 2 ) ( 7 )

Deferred revenue 38 ( 155 )

Changes in other non-current assets 58 8

Other non-current assets 24 40

Net cash used in operating activities ( 1,246 ) ( 3,069 )

Cash Flows From Investing Activities:

Proceeds from maturities of short-term investments - 7,500

Capital expenditures for property and equipment ( 5 ) ( 2 )

Investment in patents and trademarks ( 156 ) ( 124 )

Net cash (used in) provided by investing activities ( 249 ) 7,363

Investment in patents, trademarks and other intangibles ( 53 ) ( 44 )

Net cash paid for acquisition - ( 54 )

Net cash used in investing activities ( 58 ) ( 100 )

Cash Flows From Financing Activities:

Proceeds from exercise of stock options - 588

Proceeds from issuance of Series B convertible preferred stock 4,500 -

Proceeds from issuance of warrants and common stock, net of offering costs 5,728 -

Dividends settled in cash - ( 120 )

Proceeds from private placement 5,000 -

Proceeds from warrant exercise 100 -

Proceeds from issuance of common stock and warrants, net - 5,729

Net cash provided by financing activities 5,100 5,729

3 unchanged sentences

Supplemental Disclosure of Non-Cash Investing and Financing Activities:

Reclassification of warrant liabilities to additional paid in capital $ 12,151 $ 94

Dividends on convertible preferred stock $ ( 492 ) $ ( 1,017 )

Dividends declared on convertible preferred stock $ ( 249 ) $ ( 164 )

Dividends settled with common stock $ 249 $ 164

6 unchanged sentences

Wrap Technologies, Inc., a Delaware corporation (the “Company”, “we”, “us”, and “our”), is a publicly traded company with its common stock, par value $ 0.0001 per share (“Common Stock”), listed on the Nasdaq Capital Market (“Nasdaq”) under the trading symbol “WRAP.” The Company is a developer and supplier of public safety products and training services for law enforcement and security personnel.

The Company’s primary product is the BolaWrap® remote restraint device.

The principal markets for the Company’s proprietary products and services are in North and South America, Europe, Middle East and Asia.

The Company's product and service portfolio also includes Wrap Reality, a virtual reality training simulator, WrapTactics™, a subscription-based digital training platform, WrapVision™, a body-worn camera and digital evidence management solution, and technology-enabled services including managed services and policy support.

The principal markets for the Company's proprietary products and services are in North and South America, Europe, the Middle East, and Asia.

Basis of Presentation

9 unchanged sentences

The condensed consolidated financial statements and notes thereto should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2025, included in the

Company’s Annual Report on Form 10-K for the year ended December 31, 2024 (the “ Annual Report ”), as filed with the SEC on March 31, 2025 and as amended on April 25, 2025.

The accompanying unaudited condensed consolidated balance sheet as of September 30,

2025 has been derived from the audited consolidated balance sheet as of December 31, 2024, contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2024.

Company’s Annual Report on Form 10-K for the year ended December 31, 2025 (the “ Annual Report ”), as filed with the SEC on March 26, 2026.

The accompanying unaudited condensed consolidated balance sheet as of March 31, 2026 has been derived from the audited consolidated balance sheet as of December 31, 2025, contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2025.

Results of operations for interim periods are not necessarily indicative of the results of operations for a full year.

Where necessary, the prior year’s information has been reclassified to conform to the current year’s presentation.

Principles of Consolidation

The Company has three wholly owned subsidiaries, Wrap Reality, Inc., that sells a virtual reality (“ VR ”) training system primarily targeting law enforcement agencies, Intrensic, LLC (“Intrensic”), specializing in Body Worn Camera and Digital Evidence Management solutions and Wrap Federal, LLC.

The condensed consolidated financial statements include the accounts of these subsidiaries after elimination of intercompany transactions and accounts.

Segment and Related Information

The Company operates as a single segment.

The Company’s chief operating decision maker is Scot Cohen, the Company’s Executive Chairman and Chief Executive Officer, who manages operations for purposes of allocating resources.

Refer to Note 15.

Major Customers and Related Information for further discussion.

Goodwill represents the difference, if any, between the aggregate consideration paid for an acquisition and the fair values of the underlying net assets

and liabilities assumed from an acquired business.

Goodwill is not amortized but instead is tested for impairment.

The Company tests goodwill for impairment on an annual basis during the fourth quarter, or more frequently if conditions indicate that

such impairment could exist.

The Company evaluates qualitative factors to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying value and whether it is necessary to perform goodwill impairment

Definite-lived Intangible Assets

Definite-lived intangible assets represent certain trade names, patents, licenses, software, acquired technology and customer relationships.

Definite-lived intangible assets are recorded at cost less any accumulated amortization and accumulated impairment losses, if any.

Definite-lived intangible assets acquired through the business combination are measured at fair value at the acquisition date.

The Company amortizes these acquired definite-lived intangibles assets with a finite life on a straight-line basis, over 6 years for technology;

between 3 and 7 years for customer relationships;

and 8 years for trademarks and trade names.

The Company operates as a single operating and reportable segment.

The Company's Chief Operating Decision Maker is its Chief Executive Officer, who manages operations for purposes of allocating resources on a consolidated basis.

Use of Estimates

The preparation of financial statements in conformity with U.S.

GAAP requires management to make estimates and assumptions (e.g., stock-based

compensation valuation, allowance for doubtful accounts, valuation of inventory and intangible assets, warranty reserve, accrued expense, valuation of warrants, and recognition and measurement of contingencies) that affect the reported amounts of

assets and liabilities, and disclosure of contingent assets and liabilities at the date of the financial statements and affect the reported amounts of revenue and expense during the reporting period.

Actual results could materially differ from those

The Company accounts for warrants as liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative

guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”).

The assessment considers whether the

warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants

are indexed to the Company’s own shares of Common Stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification.

assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

For issued warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on

the date of issuance, and each balance sheet date thereafter.

The Company accounts for the warrants issued in accordance with the guidance contained in ASC 815-40-15-7C, under which the warrants do not meet the criteria for equity treatment and must

be recorded as liabilities.

Accordingly, the Company classifies the warrants as liabilities at their fair value and adjusts the warrants to fair value at each reporting period.

This liability is subject to re-measurement at each balance sheet date

until exercised, and any change in fair value is recognized in the Company’s condensed consolidated statement of operations.

On June 30, 2025, the Company entered into the Series A Warrant Amendment (as defined herein) and the 2025 Warrant Amendment (as defined herein).

result, the Series A Warrants (as defined herein) and the PIPE Warrants (as defined herein), each satisfy the requirements outlined in ASC 815-10-15-74(a)(1) and in ASC 815-10-15-74(a)(2).

Under ASC 815-40-35-10, the amended instruments qualify for

equity-classification on a prospective basis.

The effective date of the relating reclassification from warrant liabilities to additional paid-in capital was June, 30, 2025.

See Footnote 8:

Warrants for additional detail.

Series A Preferred Stock

The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with ASC 480 and ASC 815 to determine if

those instruments or embedded components of those instruments qualify as derivatives and are subject to bifurcation accounting.

The Company determines that the economic characteristics and risks of the embedded derivative instrument are clearly and

closely related to the economic characteristics and risks of the host contract.

The convertible instruments are accounted for as a single hybrid instrument.

Additionally, the convertible instruments do not have any redemption features that would

preclude permanent equity classification in accordance with the guidance contained in ASC 480-10-S99.

The Company issued the Series A Warrants (as defined herein), which are classified as liabilities and measured at fair value on a recurring basis, and the Company's Series A Convertible Preferred Stock, par value $ 0.0001 per share (the “Series A Preferred Stock”) in one transaction.

The proceeds from the issuances were allocated by using the with-and-without method.

Under this method, the Company first allocated the proceeds to the Series A Warrants based on their initial fair value measurement and then allocated the remaining proceeds to the Series A Preferred Stock.

On June 30, 2025, the Company and holders of the Series A Warrants amended the Series A Warrants, which allowed the Company to account for the Series A Warrants as equity under ASC 480 and a reclassification was recorded from warrant liability to additional paid-in-capital.

GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period.

Actual results could materially differ from those estimates.

Revenue Recognition

The Company recognizes revenue under ASC Topic 606 - Revenue from Contracts with Customers (“ASC 606”).

Revenue is recognized when control of the

promised goods or performance obligations for services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for the goods or services.

The Company enters into contracts that include various combinations of products, accessories, software and services, each of which are generally distinct

and are accounted for as separate performance obligations.

Product sales include BolaWrap products and accessories.

Managed services revenue represents the consulting services provided to customers of W1 Global, LLC (“W1”).

Other revenue includes VR

revenues, service, training and shipping revenues.

The timing of revenue recognition may differ from the timing of invoicing to customers.

The Company generally has an unconditional right to consideration

when customers are invoiced, and a receivable is recorded.

A contract asset is recognized when revenue is recognized prior to invoicing, or a contract liability (deferred revenue) when revenue will be recognized after invoicing.

recognizes an asset if there are incremental costs of obtaining a contract with a customer such as commissions.

These costs are ascribed to or allocated to the underlying performance obligations in the contract.

The Company may receive consideration,

per the terms of a contract, from customers prior to transferring goods to the customer.

The Company records customer deposits as a contract liability.

Additionally, the Company may receive payments, most typically for service and warranty contracts, at

the onset of the contract and before the services have been completed.

In such instances, a deferred revenue liability is recorded.

The Company recognizes these contract liabilities as revenue after all revenue recognition criteria are met.

Estimated costs for the Company’s standard warranty, generally one-year, are charged to cost of products sold when revenue is recorded for the related

Royalties are also charged to the cost of products sold.

Revenue is recognized when control of promised goods or services is transferred to customers in an amount that reflects the consideration the Company expects to receive.

The Company's revenues consist of product sales (BolaWrap devices, cassettes, and accessories) and technology-enabled services (software subscriptions, body-worn cameras, managed services, policy support, training, and shipping).

As of March 31, 2026, all outstanding warrants (Series A Warrants, PIPE Warrants, Series B Warrants, and February 2026 Warrants each defined herein) are classified within permanent equity (additional paid-in capital) following amendments executed on June 30, 2025 that enabled equity classification under ASC 815-40 as discussed further in Note 8.

These warrants are not subject to subsequent fair value remeasurement and no warrant liability is recorded as of March 31, 2026 or December 31, 2025.

Loss per Share

Basic loss per share (EPS) is computed by dividing net loss, less any dividends, accretion or decretion, redemption or induced conversion, if any, on the

Company’s Series A Preferred Stock, by the weighted average number of shares outstanding during the reported period.

In computing diluted EPS, the Company adjusts the numerator used in the basic EPS computation, subject to anti-dilution requirements, to add back the dividends (declared or cumulative undeclared) applicable to the Series A Preferred Stock.

Such add-back would also include any adjustments to equity in the period to accrete the Series A Preferred Stock to its redemption price, or recorded upon a redemption or induced conversion, if any.

The Company adjusts the denominator used in the basic EPS computation, subject to anti-dilution requirements, to include the dilution from potential shares resulting from the issuance of the Series A Preferred Stock, restricted stock units, and stock options.

Stock options and restricted stock units exercisable or issuable for a total of 7,089,678 shares and 4,979,745 shares of Common Stock were outstanding as of September 30, 2025 and 2024, respectively.

Company’s Series A Convertible Preferred Stock ("Series A Preferred Stock"), by the weighted average number of shares outstanding during the reported period.

Such add-back would also include any adjustments to equity in the period to accrete the Series A and Series B Convertible Preferred Stock to its redemption price, or recorded upon a redemption or induced conversion, if any.

The Company adjusts the denominator used in the basic EPS computation, subject to anti-dilution requirements, to include the dilution from potential shares resulting from the issuance of the Series A and Series B Convertible Preferred Stock, restricted stock units, and stock options.

Stock options and restricted stock units exercisable or issuable for a total of 11,369,761 shares and 7,595,515 sh ares of Common Stock were outstanding as of March 31, 2026 and 2025, respectively.

These securities are not included in the computation of diluted net loss per share of Common Stock for the periods presented as their inclusion would be antidilutive due to losses incurred by the Company.

Reclassifications

Certain prior year amounts have been reclassified to conform to the current year presentation.

These reclassifications had no effect on previously reported net loss, total assets, total liabilities, stockholders’ equity, or cash flows.

Recently Issued Accounting Guidance Not Yet Effective

In November 2024, the FASB issued ASU No.

2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic

Disaggregation of Income Statement Expenses (“ASU 2024-03”), which requires disaggregation of certain costs and expenses, including employee compensation, and requires other improvements to disclosures.

The amendments in this update

are effective for annual periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027.

The update may be applied on a prospective or retrospective basis.

The Company is evaluating the impact of ASU 2024-03

on the Company’s notes to the consolidated financial statements.

In November 2024, the FASB issued ASU 2024-03, which requires disaggregated disclosure of income statement expenses for public business entities.

ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027.

The Company is currently evaluating the impact of ASU 2024-03 on its financial statements.

REVENUE AND PRODUCT COSTS

Revenue consists of product revenue, technology enabled services, and managed services.

Product sales include BolaWrap products and accessories.

Technology enabled services includes VR revenue, service, training and shipping revenue.

Managed services revenue includes consulting services delivered to third parties and billed on an agreed hourly fee basis when enforceable right to payment

The timing of revenue recognition may differ from the timing of invoicing to customers.

The Company generally has an unconditional right to consideration

when customers are invoiced, and a receivable is recorded.

A contract asset is recognized when revenue is recognized prior to invoicing, or a contract liability (deferred revenue) when revenue will be recognized subsequent to invoicing.

recognizes an asset if there are incremental costs of obtaining a contract with a customer such as commissions.

These costs are ascribed to or allocated to the underlying performance obligations in the contract.

The Company may receive consideration,

per the terms of a contract, from customers prior to transferring goods to the customer.

The Company records customer deposits as a contract liability.

Additionally, the Company may receive payments, most typically for service and warranty contracts, at

the onset of the contract and before the services have been completed.

In such instances, a deferred revenue liability is recorded.

The Company recognizes these contract liabilities as revenue after all revenue recognition criteria are met.

costs for the Company’s standard warranty, generally one-year, are charged to cost of products sold when revenue is recorded for the related product.

Royalties are also charged to the cost of products sold.

The table below details the activity in our contract liabilities during the nine months ended September 30, 2025.

Revenues consist of product sales and technology-enabled services.

Product sales include BolaWrap devices, cassettes, and accessories.

Technology-enabled services include software subscriptions, body-worn cameras, managed services, policy and training support, and shipping revenue.

The table below details the activity in our contract liabilities during the three months ended March 31, 2026.

SCHEDULE OF CONTRACT LIABILITIES

Customer Deferred

Deposits Revenue

Customer Deposits Deferred Revenue

Balance at January 1, 2026 $ 62 $ 422

1 unchanged sentence

Transfer to revenue ( 30 ) ( 221 )

Balance at September 30, 2025 $ 61 $ 400

Balance at March 31, 2026 $ 51 $ 460

Current portion $ 51 $ 449

Long-term portion $ - $ 11

As of September 30, 2025, the Company’s deferred revenue of $ 400 consisted of $ 15 related to BolaWrap extended warranties and services, $ 20 related to WRAP Ready, $ 289 related to Intrensic extended warranties and services, $ 39 related to VR, and $ 37 related to training.

As of March 31, 2026, the Company’s deferred revenue of $ 460 consisted of $ 9 related to BolaWrap extended warranties and services, $ 27 related to WRAP Ready, $ 379 related to Intrensic extended warranties and services, $ 21 related to VR, $ 14 related to training and $ 10 related to WrapTactics.

FINANCIAL INSTRUMENTS

15 unchanged sentences

no market data.

The following table shows the Company’s short-term investments by significant investment category as of September 30, 2025, and December 31, 2024.

As of September 30, 2025

Adjusted Unrealized Unrealized Market

Cost Gains Losses Value

The following table shows the Company’s short-term investments by significant investment category as of March 31, 2026, and December 31, 2025.

As of March 31, 2026

Cost Unrealized

Gains Unrealized

Losses Market

Money Market Funds $ 640 $ - $ - $ 640

1 unchanged sentence

As of December 31, 2025

Adjusted Unrealized Unrealized Market

Cost Gains Losses Value

Cost Unrealized

Gains Unrealized

Losses Market

Money Market Funds $ 639 $ - $ - $ 639

Total financial assets $ 639 $ - $ - $ 639

Unrealized gains or losses resulting from our short-term investments are recorded in accumulated other comprehensive gain or loss as they are classified

as available for sale.

During the nine months ended September 30, 2025, as well as the nine months ended September 30, 2024, no gain (loss) was recorded to comprehensive loss.

The warrant liabilities are measured at fair value on a recurring basis.

The subsequent measurement of the warrant liabilities as of September 30, 2025, is

classified as Level 3 due to the use of an observable market quote in a non-active market and the management’s assumption of the expected stock price volatility.

The following table presents the fair value in the beginning of the period, the changes in the fair value, and the fair value at the end of the period of the warrant liabilities:

SCHEDULE OF FAIR OF WARRANT LIABILITIES

September 30, 2025 December 31, 2024

Fair value at inceptions for December 31, 2024 or the beginning of the period for September 30, 2025 $ ( 10,131 ) $ ( 19,703 )

Warrants issued with Private Placement ( 5,178 ) -

Change in fair value of warrant liabilities 3,158 9,572

Reclassification of warrant liabilities to equity 12,151 -

Fair value as of period end $ - $ ( 10,131 )

The Company used a Monte Carlo simulation to estimate the fair value of warrant liabilities as of June 30, 2025, being the date the Company entered into the Series A Warrant Amendment and the 2025 Warrant Amendment.

Under ASC 815-40-35-10, the amended instruments qualify for equity-classification on a prospective basis.

The effective date of the relating reclassification from warrant liabilities to additional paid-in capital was June, 30, 2025 (the "Reclassification Date").

The valuation was performed based on the amended terms of the Series A Warrants and PIPE Warrants.

The following table summarizes the assumptions used to compute the fair value of the Company’s warrants:

MONTE CARLO SIMULATION MODEL – PIPE WARRANTS

June 30, 2025

Reclassification Date

Expected stock price volatility 86 %

Risk-free interest rate 3.73 %

Dividends yield 0 %

Terms (years) 4.5

Strike Price $ 1.45

Stock Price $ 1.56

Fair Value Per Warrant Share $ 1.235

MONTE CARLO SIMULATION MODEL – 2025 WARRANTS

June 30, 2025

Reclassification Date

Expected stock price volatility 89 %

Risk-free interest rate 3.77 %

Dividends yield 0 %

Terms (years) 5.15

Strike Price $ 1.8

Stock Price $ 1.56

Fair Value Per Warrant Share $ 1.132

The Company used the modified Black-Scholes option pricing model to determine the fair value of warrant liabilities as of December 31, 2024.

following table summarizes the assumptions used to compute the fair value of the Company’s warrants:

December 31, 2024

Expected stock price volatility 88 %

Risk-free interest rate 4.25 %

Dividends yield 0 %

Weighted average expected life of warrants (years) 3.5

Weighted average exercise price $ 1.45

Our other financial instruments also include accounts receivable, accounts payable, accrued liabilities and customer deposits.

Due to the short-term

nature of these instruments, their fair values approximate their carrying values on the balance sheet.

Inventory is recorded at the lower of cost or net realizable value.

The cost of substantially all the Company’s inventory is determined by the FIFO cost method.

As of March 31, 2026 and December 31, 2025, the Company has no warrant liabilities.

All outstanding warrants are classified within permanent equity following amendments completed on June 30, 2025.

Refer to Note 8 for further discussion.

Other financial instruments, including accounts receivable, accounts payable, accrued liabilities and customer deposits, are carried at cost which approximates fair value due to their short-term nature.

Inventory is recorded at the lower of cost or net realizable value using the weighted average cost method.

Inventories consisted of the following:

SCHEDULE OF INVENTORY

September 30, 2025 December 31, 2024

March 31, 2026 December 31, 2025

Finished goods $ 3,198 $ 3,509

2 unchanged sentences

Inventories, net $ 4,645 $ 4,971

Inventory reserve expense was $ 83 and $ 270 for the three and nine months ended September 30, 2025, respectively, and $ 0 and $ 12 for the three and nine months ended September 30, 2024, respectively.

Inventory reserve expense was $ 0 and $ 18 for the three months ended March 31, 2026 and 2025, respectively.

PROPERTY AND EQUIPMENT, NET

1 unchanged sentence

SCHEDULE OF PROPERTY AND EQUIPMENT

September 30, 2025 December 31, 2024

March 31, 2026 December 31, 2025

Production and lab equipment $ 391 $ 391

2 unchanged sentences

Furniture, fixtures and improvements 81 81

$ 1,214 $ 1,351

Property and equipment, gross $ 1,230 $ 1,225

Accumulated depreciation ( 1,125 ) ( 1,102 )

Property and equipment, net $ 105 $ 123

Depreciation expense was $ 25 and $ 92 for the three and nine months ended September 30, 2025, respectively, and $ 82 and $ 312 for the three and nine months ended September 30, 2024, respectively.

Depreciation expense was $ 23 and $ 40 for the three months ended March 31, 2026 and 2025, respectively.

INTANGIBLE ASSETS

1 unchanged sentence

Intangible assets, net consisted of the following:

September 30, 2025 December 31, 2024

March 31, 2026 December 31, 2025

Amortizable intangible assets:

2 unchanged sentences

Purchased software and technology 512 512

Customer Relationships 160 160

$ 3,344 $ 3,189

Gross amortizable intangibles $ 2,074 $ 2,021

Accumulated amortization ( 903 ) ( 870 )

Total amortizable $ 1,726 $ 1,933

Total amortizable, net $ 1,171 $ 1,151

Indefinite life assets (non-amortizable) 421 421

Total intangible assets, net $ 1,592 $ 1,572

Amortization expense was $ 125 and $ 362 for the three and nine months ended September 30, 2025, respectively, and $ 114 and $ 334 for the three and nine months ended September 30, 2024, respectively.

The Company recognized impairment charges for Customer Relationships of $ 54 and $ 54 for the three and nine months ended September 30, 2025, respectively, related to the managed services realignment.

No impairment charges were recognized in the three and nine months ended September 30, 2024.

As of September 30, 2025, future amortization expense is as follows:

Amortization expense was $ 33 and $ 115 for the three months ended March 31, 2026 and 2025 respectively.

As of March 31, 2026, future amortization expense is as follows:

2026 (9 months) $ 88

Thereafter 619

Total $ 1,171

ACCOUNTS PAYABLE AND

1 unchanged sentence

Accrued liabilities consist of the following:

SCHEDULE OF ACCRUED LIABILITIES

September 30, 2025 December 31, 2024

March 31, 2026 December 31, 2025

Patent and legal costs $ 134 $ 111

2 unchanged sentences

Royalty 99 99

Contract settlement 31 300

Accrued purchases - 6

Taxes and other 119 159

Total $ 563 $ 1,403

Total accrued liabilities $ 531 $ 407

Changes in our estimated product warranty costs were as follows:

Nine Months Ended September 30,

Three Months Ended March 31,

Balance, beginning of period $ 30 $ 83

3 unchanged sentences

SCHEDULE OF PRODUCT WARRANTY LIABILITY

On June 29, 2023, the Company entered into a Securities Purchase Agreement (the “Series A Purchase Agreement”) with certain directors of the Company and certain accredited and institutional investors (collectively, the “Series A Investors”), pursuant to which it agreed to sell to the Series A Investors in a registered direct offering (the “Series A Offering”):

(i) an aggregate of 10,000 shares of the Company’s newly-designated Series A Convertible Preferred Stock, with par value $ 0.0001 per share and a stated value of $ 1,000 per share (the “Series A Preferred Stock”), initially convertible into up to 6,896,553 shares of Common Stock, at an initial conversion price of $ 1.45 per share (the “Conversion Price”), and (ii) warrants to acquire up to an aggregate of 6,896,553 shares of Common Stock (the “Series A Warrants”).

Each Series A Warrant has an exercise price of $ 1.45 per share, became exercisable after the date that was six months from the date of issuance and will expire 5 years following the date of issuance.

The exercise price is subject to customary adjustments for stock dividends, stock splits, reclassifications and the like, and subject to price-based adjustment, on a “full ratchet” basis, in the event of any issuances of Common Stock, or securities convertible, exercisable or exchangeable for Common Stock, at a price below the then-applicable exercise price (subject to certain exceptions).

The closing of the Series A Offering occurred on July 3, 2023.

The aggregate gross proceeds from the Series A Offering were $ 10,000 , of which $ 7,717 was allocated to the Series A Warrants.

On February 24, 2025, the Company entered into a securities purchase agreement (the “PIPE Purchase Agreement”) with certain accredited investors (collectively, the “PIPE Purchasers”) for the issuance and sale in a private placement (the “Private Placement”) of an aggregate of 3,216,666 shares (the “Common Shares”) of Common Stock and accompanying warrants (“PIPE Warrants”) to purchase up to 3,216,666 shares of Common Stock, with an exercise price of $ 1.80 per share.

The purchase price for one Common Share and accompanying PIPE Warrant was $ 1.80 .

The gross proceeds to the Company were $ 5,790 before estimated offering expenses payable by the Company, of which $ 5,185 was allocated to the PIPE Warrants.

On June 30, 2025, the Company entered into a warrant amendment (the “Series A Warrant Amendment”) with the Required Holders (as defined in the Series A Purchase Agreement), pursuant to which, the Required Holders agreed to amend the terms of the Series A Warrants to make certain adjustments to the definition of “Black Scholes Value” in each of the Series A Warrants, as described in the Series A Warrant Amendment, such that the underlying price per share as used in such calculation equals the sum of the price per share being offered in cash in the applicable Fundamental Transaction (as defined in the Series A Warrants), if any, plus the value of the non-cash consideration being offered in the applicable Fundamental Transaction, if any.

As consideration for entering into the Series A Warrant Amendment, the Company and the Required Holders agreed to amend the term of the Series A Warrants to be six and one-half years from the date of issuance.

Additionally, on June 30, 2025, the Company entered into a warrant amendment (the “2025 Warrant Amendment”) with certain of the PIPE Purchasers, pursuant to which, such PIPE Purchasers agreed to amend the terms of their respective PIPE Warrants to make certain adjustments to the definition of “Black Scholes Value,” as described in the 2025 Warrant Amendment, such that the underlying price per share as used in such calculation equals the sum of the price per share being offered in cash in the applicable Fundamental Transaction (as defined in the PIPE Warrants), if any, plus the value of the non-cash consideration being offered in the applicable Fundamental Transaction, if any.

As consideration for entering into the 2025 Warrant Amendment, the Company and the applicable PIPE Purchasers agreed to amend the term of their respective 2025 Warrants to be five and one-half years from the date of issuance.

Under ASC 815-40-35-10, upon effective amendment on June 30, 2025, each of the Series A Warrants and PIPE Warrants qualify for equity-classification.

Immediately before the equity reclassification, such warrants were each revalued at fair value with the resulting gain or loss being recorded in the Statement of Operations.

After fair value remeasurement, the reclassification from warrant

liabilities to additional paid-in capital was completed.

See Footnote 3:

Financial Instruments for details of the fair value measurement and impact on the Statement of Operations.

On August 18, 2025, the

Company entered into a securities purchase agreement (the “Series B Purchase

Agreement”) with certain accredited investors (collectively, the “Series B

Purchasers”) for the issuance and sale in a private placement (the “Series B

Private Placement”) of an aggregate of (i) 4,500 shares of the Company’s

newly-designated Series B Convertible Preferred Stock, with a par value of

$ 0.0001 per share and a stated value of $ 1,000 per share, initially convertible

into up to 3,000,000 shares of Common Stock, at an initial conversion price of

$ 1.50 per share (the “Series B Preferred Stock”), and (ii) accompanying

warrants (“Series B Warrants”) to purchase up to 3,000,000 shares of Common

Stock, with an initial exercise price of $ 1.50 per share.

The Series B Warrants

and the shares of Series B Preferred Stock will be exercisable or convertible,

respectively, into shares of Common Stock (“Series B Conversion Shares”)

beginning on the effective date of stockholder approval of (i) under Nasdaq

Stock Market Rule 5635(d), the issuance of shares of Common Stock in excess of

19.99% of the Company’s issued and outstanding shares of Common Stock at prices

below the “Minimum Price” (as defined in Rule 5635 of the Rules of the Nasdaq

Stock Market) on the date of the Series B Purchase Agreement pursuant to the

terms of the Series B Preferred Stock and the Series B Warrants, and (ii) an

increase in the authorized shares of the Company (the “Series B Stockholder

As of the date of this Quarterly Report on Form 10-Q, the Company

has not obtained the Series B Stockholder Approval.

However, the Company plans

to hold a special meeting of its stockholders on December 12, 2025, to, among

other things, obtain the Series B Stockholder Approval.

The Series B Warrants

will expire five years from the effective date of the Series B Stockholder

All outstanding warrants are classified within permanent equity as of March 31, 2026 and December 31, 2025.

The following summarizes the Company's outstanding warrants:

Series A Warrants — On June 29, 2023, the Company issued warrants (the "Series A Warrants") to purchase up to 6,896,553 shares of Common Stock at an exercise price of $ 1.45 per share in connection with the Series A Preferred Stock offering.

On June 30, 2025, the Company entered into an amendment agreement (the "Series A Warrant Amendment") with the Required Holders (as defined in the Series A Warrants), which resulted in reclassification of the Series A Warrants from warrant liabilities to additional paid-in capital under ASC 815-40.

The amended warrants expire on January 3, 2030 ( six and one-half years from original issuance).

PIPE Warrants — On February 24, 2025, the Company issued warrants (the "PIPE Warrants") to purchase up to 3,216,666 shares of Common Stock at an exercise price of $ 1.80 per share in connection with a private placement.

On June 30, 2025, the Company entered into an amendment agreement (the "2025 Warrant Amendment") with the PIPE holders, resulting in reclassification from warrant liabilities to additional paid-in capital under ASC 815-40.

The amended PIPE Warrants expire five and one-half years from the original issuance date.

Series B Warrants — On August 18, 2025, the Company issued warrants (the "Series B Warrants") to purchase up to 3,000,000 shares of Common Stock at an exercise price of $ 1.50 per share in connection with the Series B Convertible Preferred Stock, par value $ 0.0001 per share (the "Series B Preferred Stock") private placement.

The Series B Warrants became exercisable on December 12, 2025, the date stockholder approval was obtained, and expire on December 12, 2030 .

The Series B Warrants are classified within permanent equity.

February 2026 Warrants — On February 3, 2026, the Company issued pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 800,000 shares of Common Stock at an exercise price of $ 0.0001 per share and common warrants (the "February 2026 Common Warrants") to purchase up to 2,500,000 shares of Common Stock at an exercise price of $ 2.30 per share in connection with a private placement.

The Pre-Funded Warrants and the February 2026 Common Warrants were classified as equity within additional paid-in capital under ASC 815-40 upon issuance.

The Pre-Funded Warrants expire when exercised in full, and the February 2026 Common Warrants expire on February 3, 2031, five years from the date of issuance.

The Company determines if an arrangement is a lease at inception.

8 unchanged sentences

lease incentives and initial direct costs incurred.

For leases beginning on or after January 1, 2019, lease components are accounted for separately from non-lease components for all asset classes.

January 21, 2023, the Company’s lease was amended to extend the expiration date to July 31, 2025.

Upon execution of the amendment, which was deemed a lease modification, the Company reassessed the lease liability using the discount rate determined at

the modification date and recorded an additional ROU asset for the same amount.

The Company’s lease contains renewal provisions and escalating rental clauses and generally requires the Company to pay utilities, insurance, taxes and other operating

The renewal provisions of the existing lease agreement were not included in the determination of the operating lease liabilities and the ROU assets.

The Company also reassessed the lease classification and concluded that the lease continues

to be an operating lease.

Amortization expense was $ 76 and $ 204 for the three and nine months ended September 30, 2025, respectively, and $ 74 and $ 217 for the three and nine months ended September 30, 2024, respectively.

Operating lease expense for capitalized operating leases included in operating activities was $ 154 and $ 463 for the three and nine months ended September 30, 2025, respectively, and $ 154 and $ 463 for the three months and nine months ended September 30, 2024, respectively.

Operating lease obligations recorded on the balance sheet at September 30, 2025 are:

SCHEDULE OF OPERATING LEASE OBLIGATIONS

Amortization expense was $ 54 and $ 74 for the three months ended March 31, 2026 and 2025 respectively.

Operating lease expense for capitalized operating leases included in operating activities was $ 112 and $ 156 for the three months ended March 31, 2026 and 2025, respectively.

Operating lease obligations recorded on the balance sheet at March 31, 2026 are:

March 31, 2026

Operating lease liability — short term $ 90

1 unchanged sentence

Total operating lease liability $ 459

Future lease payments included in the measurement of lease liabilities on the balance sheet at September 30, 2025 for future periods are as follows:

SCHEDULE OF OPERATING LEASE OBLIGATIONS

Future lease payments included in the measurement of lease liabilities on the balance sheet at March 31, 2026 for future periods are as follows:

2026 (9 months) $ 90

Thereafter 813

Total future minimum lease payments 540

Less imputed interest ( 81 )

Total $ 2,491

The weighted average remaining lease term is 4.5 years, and the weighted average discount rate is 7.5 % .

1 unchanged sentence

These expenses are treated as variable lease payments and recognized in the period in which the obligation for those payments was incurred.

The Company had $ 2 and $ 33 variable lease expenses for the three and nine months ended September 30, 2025, respectively, and $ 23 and $ 41 variable lease expenses for the three and nine months ended September 30, 2024, respectively.

The Company had no short-term lease expenses for the three and nine months ended September 30, 2025, respectively, and had $ 1 and $ 16 in short-term lease expenses for the three and nine months ended September 30, 2024, respectively.

The Company had $ 0 and $ 23 variable lease expenses for the three months ended March 31, 2026 and 2025, respectively.

The Company had no short-term lease expenses for the three months ended March 31, 2026 and 2025 respectively.

The Company does not have any finance leases.

On February 13, 2026, the Company entered into a Termination and Mutual Release Agreement with the landlord of the Company's office space located at 3480 Main Highway, Suite 202, Miami, Florida 33133.

Pursuant to the agreement, the office lease dated September 20, 2023 was terminated effective as of February 13, 2026, and the Company surrendered possession of the premises.

The landlord agreed to refund the prorated portion of February 2026 rent attributable to the period following the termination date and to return the security deposit in accordance with the terms of the original lease.

The parties exchanged mutual releases of all claims arising out of or relating to the lease, except for obligations expressly set forth in the termination agreement and any obligations that by their terms survive termination.

In March 2026, the Company entered into a month-to-month service agreement for a business address located at 3350 Virginia Street, Miami, Florida 33133.

STOCKHOLDERS’ EQUITY

The Company’s authorized capital consists of 150,000,000 shares of Common Stock and 5,000,000 shares of preferred stock, par value $ 0.0001 per share (“Preferred Stock”), of which 10,000 and 4,500 are designated as Series A and Series B Preferred Stock, respectively.

The Company's authorized capital consists of 200,000,000 shares of Common Stock and 5,000,000 shares of preferred stock, par value $ 0.0001 per share, of which 10,000 shares are designated as Series A Convertible Preferred Stock and 4,500 shares are designated as Series B Convertible Preferred Stock.

Series A Preferred Stock

On July 3, 2023, the Company filed the Certificate of Designations of the Series A Preferred Stock (the “Certificate of Designations”) with the Secretary of State of the State of Delaware, designating 10,000 shares of its Preferred Stock as Series A Convertible Preferred Stock.

The terms of the Series A Preferred Stock are as set forth in the form of Certificate of Designations of the Series A Preferred Stock (the “Certificate of Designations”).

The Series A Preferred Stock is convertible into shares of Common Stock (the “Conversion Shares”) at the election of the holder at any time at an initial conversion price of $ 1.45 (the “Conversion Price”).

The Conversion Price is subject to customary adjustments for stock dividends, stock splits, reclassifications and the like, and subject to price-based adjustment in the event of any issuances of Common Stock, or securities convertible, exercisable or exchangeable for common stock, at a price below the then-applicable Conversion Price (subject to certain exceptions).

The holders of the Series A Preferred Stock are entitled to dividends of 8 % per annum, compounded monthly, which are payable in cash or shares of Common Stock, or a combination thereof, at the Company’s option in accordance with the terms of the Certificate of Designations.

Upon the occurrence and during the continuance of a Triggering Event (as defined in the Certificate of Designations), the Series A Preferred Stock will accrue dividends at the rate of 20 % per annum.

If the Company elects to pay any dividends in shares of Common Stock, the Conversion Price used to calculate the number of shares issuable will be equal to the lower of (i) the then applicable Conversion Price and (ii) 85 % of the arithmetic average of the three (3) lowest closing prices of the Company’s Common Stock during the twenty (20) consecutive trading day period ending on the trading day immediately preceding the dividend payment date, provided that such price shall not be lower than the lower of (x) $ 0.2828 (subject to adjustment for stock splits, stock dividends, stock combinations, recapitalizations or other similar events ) and (y) 20% of the “Minimum Price” (as defined in Nasdaq Stock Market Rule 5635) on the date of the Stockholder Approval (subject to adjustment for stock splits, stock dividends, stock combinations, recapitalizations or other similar events) or, in any case, such lower amount as permitted, from time to time, by the Nasdaq Stock Market.

On August 19, 2024, the Company entered into an Amendment Agreement (the “August 2024 Amendment”) with the Required Holders (as defined in the Certificate of Designations).

Pursuant to the August 2024 Amendment, the Required Holders agreed that (A) the unpaid and accrued dividends on the Series A Preferred Stock due July 1, 2024 (the “July Delinquent Dividend Amount”), shall be payable, at the option of the Company, in (i) cash and/or (ii) shares of Common Stock, at a price per share of Common Stock equal to the lower of (x) $ 1.00 and (y) the Dividend Conversion Price (as defined in the Certificate of Designations), using July 1, 2024, as the applicable date of determination in accordance with the Certificate of Designations;

(B) the dividends due on October 1, 2024 (the “October Dividend Amount” and, together with the July Delinquent Dividend Amount, the “Delinquent Dividend Amounts”), shall be payable in shares of Common Stock based on a per share price of Common Stock equal to 80 % of the arithmetic average of the three (3) lowest closing sale prices of the Common Stock during the month of September 2024;

and (C) such Delinquent Dividend Amounts and any Dividend Balance Shares (as defined in the Certificate of Designations), with respect thereto, if applicable, shall be delivered on October 1, 2024.

The Company and the Required Holders further agreed pursuant to the August 2024 Amendment to amend (i) the Certificate of Designations, as described below, by filing a Certificate of Amendment to the Certificate of Designations (the “August 2024 Certificate of Amendment”) and (ii) the Series A Purchase Agreement to amend the definition of “Excluded Securities.” The August 2024 Certificate of Amendment amends the Certificate of Designations to, among other things, (A) allow for the payment of dividends in the form of Common Stock to a holder of the Series A Preferred Stock who serves as a director, officer or employee of the Company;

provided that such issuance is approved by the Company’s stockholders prior to such issuance, and (B) amend certain conditions required for (i) a mandatory conversion of the Series A Preferred Stock (as described below), and (ii) the Company’s right to redeem, all or a portion, of the Series A Preferred Stock outstanding pursuant to an optional redemption (as described below), in each case, pursuant to the terms of the Certificate of Designations.

Pursuant to the August 2024 Certificate of Amendment, the Company may require holders to convert their shares of Series A Preferred Stock into shares of Common Stock if the closing price of the Company’s Common Stock exceeds $ 8.00 per share (subject to adjustment for stock splits, stock dividends, stock combinations, recapitalizations or other similar events) for 20 consecutive trading days and the daily dollar trading volume of the Common Stock exceeds $ 2,000,000 per day during the same period, provided that certain equity conditions described in the Certificate of Designations are satisfied.

Pursuant to the August 2024 Certificate of Amendment, at any time beginning 18 months from the date of the issuance, provided that the Company has filed all reports required to be filed by it pursuant to the Exchange Act on a timely basis for a continuous period of one year and provided further that certain equity conditions described in the Certificate of Designations are satisfied, the Company has the right to redeem in cash all or some of the shares of the Series A Preferred Stock outstanding at such time at a redemption price equal to the product of (x) 125 % multiplied by (y) the sum of (A) the stated value of the Series A Preferred Stock plus (B) all declared and unpaid Dividends on such Preferred Stock and any other unpaid amounts then due and payable hereunder with respect to such Series A Preferred Stock, plus (C) the make-whole amount, plus (D) any accrued and unpaid late charges with respect to such stated value and amounts payable pursuant to clause (B) as of such date of determination.

On October 14, 2024, the Company entered into an Amendment Agreement with the Required Holders (as defined in the Certificate of Designations), pursuant to which, the Required Holders agreed to amend the Certificate of Designations of the Company’s Series A Preferred Stock, as described below, by filing a Certificate of Amendment to the Certificate of Designations (the “October 2024 Certificate of Amendment”).

The October 2024 Certificate of Amendment amends the Certificate of Designations to, among other things, provide that, except as required by applicable law, the holders of the Series A Preferred Stock will be entitled to vote with holders of the Common Stock on an as converted basis, with the number of votes to which each holder of Series A Preferred Stock is entitled to be calculated assuming a conversion price of $ 1.414 per share, which was the Minimum Price (as defined in Rule 5635 of the Rule of the Nasdaq Stock Market) applicable immediately before the execution and delivery of the Series A Purchase Agreement, subject to certain beneficial ownership limitations as set forth in the Certificate of Designations.

The October 2024 Certificate of Amendment further provides that (i) certain holders of the Series A Preferred Stock will not be subject to certain beneficial ownership limitations as described in the Certificate of Designations, and (ii) stockholder approval will not be required in connection with the payment of dividends in the form of Common Stock to a holder of the Series A Preferred Stock who serves as a director, officer or employee of the Company.

The October 2024 Certificate of Amendment was filed with the Secretary of State of the State of Delaware, effective as of October 14, 2024.

The holders of the Series A Preferred Stock have no voting rights, other than with respect to certain matters affecting the rights of the Series A Preferred Stock.

On November 25, 2024, the Company entered into an Amendment and Agreement with the Series A Investors (the “November 2024 Amendment Agreement”), pursuant to which, (i) the Series A Investors agreed to amend the Certificate of Designations, as described below, by filing a Certificate of Amendment to the Certificate of Designations with the Secretary of State (the “November 2024 Certificate of Amendment”), and (ii) the Series A Investors and the Company agreed that all payment amounts that have accrued and are unpaid as of November 25, 2024, pursuant to the Certificate of Designations and the August 2024 Amendment will be satisfied by delivery of shares of Common Stock on or prior to November 25, 2024, with each Series A Investor entitled to receive the number of shares of Common Stock specified below such Series A Investor’s name on its respective signature page thereto.

The November 2024 Certificate of Amendment amends the Certificate of Designations to provide that upon the occurrence of a Triggering Event (as defined in the Certificate of Designations), the Series A Preferred Stock will accrue dividends compounded monthly at the rate of 20 % per annum.

The Certificate of Amendment became effective with the Secretary of State on December 6, 2024.

At the time of issuance, $ 2,036 of the net proceeds less transaction cost of the Series A Purchase Agreement was allocated to the 10,000 shares of Series A Preferred Stock initially issued.

As of December 31, 2024, a total of 1,793 shares of Series A Preferred Stock were converted into approximately 1,468,000 shares of Common Stock.

There were no additional conversions in the nine months ended September 30, 2025.

As of September 30, 2025, the Company has authorized, declared and paid $ 492 in dividends in the form of shares of the Company’s Common Stock during the nine months ended September 30, 2025.

For the nine months ended September 30, 2024, authorized and declared dividends totaling $ 1,017 , of which $ 60 was paid in cash, $ 129 was paid in shares of the Company’s Common Stock.

On July 3, 2023, the Company designated and issued 10,000 shares of Series A Preferred Stock (stated value $ 1,000 per share) convertible into shares of Common Stock at an initial conversion price of $ 1.45 per share.

As of March 31, 2026 and December 31, 2025, there were 8,107 and 8,207 shares outstanding, respectively.

Holders are entitled to dividends of 8 % per annum, payable in cash or shares of Common Stock at the Company's election.

For the three months ended March 31, 2026 and 2025, the Company paid dividends of $ 249 and $ 164 , respectively, in shares of Common Stock.

Series B Preferred Stock

On August 18, 2025, the Company entered into the Series B Purchase Agreement with the Series B Purchasers for the issuance and sale in a private placement of an aggregate of (i) 4,500 shares of the Company’s Series B Preferred Stock initially convertible into up to 3,000,000 shares of Common Stock, at an initial conversion price of $ 1.50 per share, and (ii) accompanying Series B Warrants to purchase up to 3,000,000 shares of Common Stock, with an initial exercise price of $ 1.50 per share.

The Series B Warrants and the shares of Series B Preferred Stock will be exercisable or convertible, respectively, into shares of Common Stock beginning on the effective date of stockholder approval of (i) under Nasdaq Stock Market Rule 5635(d), the issuance of shares of Common Stock in excess of 19.99 % of the Company’s issued and outstanding shares of Common Stock at prices below the “Minimum Price” (as defined in Rule 5635 of the Rules of the Nasdaq Stock Market) on the date of the Series B Purchase Agreement pursuant to the terms of the Series B Preferred Stock and the Series B Warrants, and (ii) an increase in the authorized shares of the Company.

As of the date of this Quarterly Report on Form 10-Q, the Company has not obtained the Series B Stockholder Approval.

However, the Company plans to hold a special meeting of its stockholders on December 12, 2025, to, among other things, obtain the Series B Stockholder Approval.

The Series B Warrants will expire five years from the effective date of the Series B Stockholder Approval.

On August 20, 2025, the Company filed the Series B Certificate of Designations, thereby creating the Series B Preferred Stock.

The Series B Certificate of Designations became effective with the Secretary of State of the State of Delaware upon filing.

The terms of the Series B Convertible Preferred Stock are as set forth in the Series B Certificate of Designations.

The Series B Preferred Stock are convertible into the Series B Conversion Shares at the election of the holders of the Series B Preferred Stock at any time at an initial conversion price of $ 1.50 per share.

The conversion price is subject to customary adjustments for stock dividends, stock splits, reclassifications, stock combinations and the like (subject to certain exceptions).

Holders of the Series B Preferred Stock shall be entitled to receive dividends when and as declared by the Board, from time to time, in its sole discretion, which dividends will be paid by the Company out of funds legally available therefor, payable, subject to the conditions and other terms of the Series B Certificate of Designations, in cash, in securities of the Company or using assets as determined by the Board on the stated value of such Series B Preferred Stock.

Except as otherwise provided in the Series B Certificate of Designations or as otherwise required by law, the Series B Preferred Stock has no voting rights.

However, as long as any shares of Series B Preferred Stock are outstanding, the Company shall not, without the affirmative vote of the holders of Series B Preferred Stock of a majority of the then outstanding shares of the Series B Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the of the Series B Preferred Stock or alter or amend the Series B Certificate of Designations, (b) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series B Preferred Stock, (c) increase the number of authorized shares of the Series B Preferred Stock, or (d) enter into any agreement with respect to any of the foregoing.

There is no established public trading market for the Series B Preferred Stock and the Company does not intend to list the Series B Preferred Stock on any national securities exchange or nationally recognized trading system.

On March 28, 2017 , the Company adopted, and the Company’s stockholders approved, the Wrap Technologies, Inc.

2017 Equity Incentive Plan (the “2017 Plan”), which was adopted by the Board on November 12, 2024, subject to stockholder approval.

Under the 2017 Plan as originally adopted, the Company initially reserved 2,000,000 shares of Common Stock for issuance as awards under the 2017 Plan.

The 2017 Plan was amended by the First Amendment to the 2017 Plan to increase the total number of shares of Common Stock for issuance under the 2017 Plan to 4,100,000 shares, which was adopted by the Board on March 16, 2019, and by stockholders on May 23, 2019.

The 2017 Plan was also amended by the Second Amendment to the 2017 Plan to increase the total number of shares of Common Stock for issuance under the 2017 Plan to 6,000,000 shares which was adopted by the Board on April 8, 2020, and by stockholders on June 5, 2020.

The 2017 Plan was also amended by the Third Amendment to the 2017 Plan to increase the total number of shares of Common Stock for issuance under the 2017 Plan to 7,500,000 shares which was adopted by the Board on April 23, 2021, and by stockholders on June 22, 2021.

The 2017 Plan was also amended by the Fourth Amendment to the 2017 Plan to increase the total number of shares of Common Stock for issuance under the 2017 Plan to 9,000,000 shares which was adopted by the Board on April 22, 2022, and by our stockholders on June 23, 2022.The 2017 Plan was amended by the Fifth Amendment to the 2017 Plan to increase the total number of shares of Common Stock for issuance under the 2017 Plan to 16,500,000 shares which was adopted by the Board on November 12, 2024, and by our stockholders on December 23, 2024.

As of September 30, 2025, there were 4,654,885 shares of Common Stock remaining available for grant under the 2017 Plan.

On August 18, 2025, the Company issued 4,500 shares of Series B Preferred Stock (stated value $ 1,000 per share) convertible up to 3,000,000 shares of Common Stock at an initial conversion price of $ 1.50 per share.

As of March 31, 2026 and December 31, 2025, there were 3,600 and 4,500 shares outstanding, respectively.

Holders are entitled to dividends when and as declared by the Board, payable in cash or shares of the Company's securities.

No dividends were declared or paid during the three months ended March 31, 2026.

The Company maintains the Wrap Technologies, Inc.

2017 Equity Incentive Plan (the "2017 Plan"), which was most recently amended on December 12, 2025 to authorize up to 20,500,000 shares of Common Stock for issuance as equity awards under the 2017 Plan.

As of March 31, 2026, there were 4,033,073 shares of Common Stock remaining available for grant under the 2017 Plan.

Stock Options

The following table summarizes stock option activity for the nine months ended September 30, 2025:

SCHEDULE OF STOCK OPTION ACTIVITY

The following table summarizes stock option activity for the three months ended March 31, 2026:

Weighted Average

Options on Remaining Aggregate

Common Exercise Contractual Intrinsic

Shares Price Term Value

Outstanding January 1, 2025 3,944,284 $ 2.12 8.30 $ 1,486

Shares Exercise Price Remaining

Terms Aggregate

Outstanding December 31, 2025 6,449,534 2.05 8.56 3,706

Granted 4,197,500 2.21 - -

1 unchanged sentence

Forfeited, cancelled, expired ( 300,000 ) 2.45 - -

Outstanding September 30, 2025 6,033,449 $ 1.91 8.38 $ 3,541

Exercisable September 30, 2025 1,625,078 $ 2.43 6.56 $ 856

As of September 30, 2025, there were 4,743,283 service-based stock options outstanding, and 1,290,166 performance-based stock options outstanding which were granted in October 2023 to the Company’s current Chief Executive Officer, subject to vesting based on future market capitalization targets.

Outstanding March 31, 2026 10,347,034 2.10 8.75 402

Exercisable March 31, 2026 3,072,524 2.31 7.79 141

As of March 31, 2026 there were 8,981,868 service-based stock options outstanding, and 1,365,166 performance-based stock options outstanding.

For the performance-based options, 1,290,166 were granted in October 2023 to the Company's current Chief Executive Officer, subject to vesting based on future market capitalization targets, and 75,000 were granted to a consultant, subject to vesting upon the Company's execution of a specified customer contract.

The Company uses the Black-Scholes option pricing model to determine the fair value of the service-based options that have been granted.

1 unchanged sentence

SCHEDULE OF STOCK OPTION ACTIVITY, FAIR VALUE OF ASSUMPTIONS

For the Nine Months Ended September 30,

Three Months Ended March 31,

Expected stock price volatility 76 % 76 %

11 unchanged sentences

Treasury bonds whose maturity period is appropriate for the term of the options.

The dividend yield of zero 0 is based on the fact that the Company has never paid cash dividends and has no present intention of paying cash dividends.

The dividend yield of 0 % is based on the fact that the Company has never paid cash dividends and has no present intention of paying cash dividends.

The Company calculates the expected life of the options using the Simplified Method for the employee stock options as the Company does not have sufficient historical exercise data.

Stock option expense was $ 295 and $ 341 for the three months ended September 30, 2025 and 2024, respectively.

Stock option expense was $ 1,158 and $ 776 for the nine months ended September 30, 2025 and 2024, respectively.

Stock option expense was $ 2,033 and $ 387 for the three months ended March 31, 2026 and 2025, respectively.

Restricted Stock Units

1 unchanged sentence

RSUs are settled in shares of the Company’s Common Stock as the RSUs vest.

The following table summarizes RSU activity for the nine months ended September 30, 2025:

SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY

Weighted Weighted

Service-Based Average Grant Average Vesting

RSU's Date Fair Value Period (Years)

Unvested at January 1, 2025 988,102 $ 2.25 3.67

The following table summarizes RSU activity for the three months ended March 31, 2026:

Weighted Average

Service-Based

RSUs Grant Date

Fair Value Vesting

Unvested at December 31, 2025 1,014,563 $ 2.23 3.62

Granted service based 81,052 2.46 -

1 unchanged sentence

Forfeited and cancelled - - -

Unvested at September 30, 2025 1,056,229 $ 2.19 2.31

Unvested at March 31, 2026 1,022,727 $ 2.25 3.69

SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY

The Company used the Monte Carlo Simulation Model to value at the grant date the aggregate of 632,911 market condition performance RSUs granted in January 2024 to the Company’s Chief Executive Officer.

1 unchanged sentence

Vesting is based on sustained market capitalization of $ 1 billion, and the derived service period is 4.3 years.

RSU expense was $ 343 and $ 555 for the three months ended September 30, 2025 and 2024, respectively.

RSU expense was $ 1,915 and $ 1,038 for the nine months ended September 30, 2025 and 2024, respectively.

RSU expense was $ 351 and $ 1,278 for the three months ended March 31, 2026 and 2025, respectively.

Share-Based Compensation Expense

The Company recorded share-based compensation for options and RSUs in its statements of operations for the relevant periods as follows:

SCHEDULE OF SHARE-BASED COMPENSATION FOR OPTIONS AND RESTRICTED STOCK UNITS

Three months ended September 30, Nine months ended September 30,

2025 2024 2025 2024

Three Months Ended March 31,

Selling, general and administrative $ 2,384 $ 1,603

1 unchanged sentence

Total share-based expense $ 2,384 $ 1,665

As of September 30, 2025, total estimated compensation cost of stock options granted and outstanding but not yet vested was $ 3,974 which is expected to be recognized over the weighted average period of 3.01 years.

As of September 30, 2025, total estimated compensation cost of RSUs granted and outstanding but not yet vested was $ 1,282 , which is expected to be recognized over the weighted average period of 2.31 years.

SCHEDULE OF SHARE-BASED COMPENSATION FOR OPTIONS AND RESTRICTED STOCK UNITS

As of March 31, 2026, total estimated compensation cost of stock options granted and outstanding but not yet vested was $ 8,707 which is expected to be recognized over the weighted average period of 2.94 years.

As of March 31, 2026, total estimated compensation cost of RSUs granted and outstanding but not yet vested was $ 1,004 , which is expected to be recognized over the weighted average period of 1.88 years.

DEFINED CONTRIBUTION PLAN

3 unchanged sentences

Eligible employees may contribute a percentage of their salary subject to certain limitations.

The Company’s contributions for each of the nine months ended September 30, 2025 and 2024 was $ 23 and $ 0 , respectively.

The Company’s matching contributions were $ 13 and $ 0 for the three months ended March 31, 2026 and 2025, respectively.

COMMITMENTS AND CONTINGENCIES

Purchase Commitments

As of September 30, 2025, the Company was committed for approximately $ 391 for future component deliveries that are generally subject to modification or rescheduling in the normal course of business.

As of March 31, 2026, the Company was committed for approximately $ 541 for future component deliveries that are generally subject to modification or rescheduling in the normal course of business.

Indemnifications and Guarantees

6 unchanged sentences

The Company has no liabilities recorded for such indemnities.

Regulatory Agencies

The Company is subject to oversight from regulatory agencies regarding firearms that arise in the ordinary course of its business.

The Company is subject to litigation and other claims in the ordinary course of business.

3 unchanged sentences

advice of legal counsel, and other information and events pertaining to a particular matter.

As of September 30, 2025, the Company had no provision for liability under existing litigation.

Facility lease

The Company entered into a facility lease agreement for its new production facility based in Norton, Virginia.

The initial term of the agreement is for five years and commenced on October 1, 2025 (the "Term").

The Company was granted early occupancy of the facility for use beginning on August 18, 2025.

The total cash payments to the lessor during the Term are $ 600 .

As of March 31, 2026, the Company had no provision for liability under existing litigation.

RELATED PARTY TRANSACTIONS

Series A Preferred Stock

On June 29, 2023, the Company entered into the Series A Purchase Agreement with certain investors, including Scot Cohen, the Company’s Chief Executive Officer, and V4 Global LLC (“V4”).

Cohen has voting and dispositive control with respect to the securities and is deemed to be the beneficial owner of the securities held by V4.

Pursuant to the Series A Purchase Agreement, the Company issued Mr.

Cohen and V4 an aggregate of 3,000 shares of Series A Preferred Stock and Series A Warrants to purchase up to an aggregate of 2,068,966 shares of Common Stock for aggregate gross proceeds of $ 3,000 .

For the nine months ended September 30, 2025, Mr.

Cohen earned dividends totaling $ 120 on his Series A Preferred Stock.

PIPE Financing

On February 24, 2025, the Company entered into the PIPE Purchase Agreement with certain accredited including:

V4 Global, LLC (“V4”), an entity controlled by Mr.

Cohen, the Company’s Chief Executive Officer;

Continuum Ventures, LLC (“Continuum”), an entity controlled by Jared Novick, the Company’s President and Chief Operating Officer;

and Savbo Investments LLC (“Savbo”), an entity controlled by Marc Savas, a member of the Company’s Board, pursuant to which, the Company issued and sold in a private placement an aggregate of 3,216,666 shares of Common Stock and PIPE Warrants with an exercise price of $ 1.80 per share, to purchase up to 3,216,666 shares of Common Stock (the “Private Placement”).

Pursuant to the PIPE Private Placement, the Company sold to (i) V4 1,100,000 shares of Common Stock and PIPE Warrants to purchase up to an aggregate of 1,100,000 shares of Common Stock, for aggregate gross proceeds of $ 1,980 , (ii) Continuum an aggregate of 275,000 shares of Common stock and PIPE Warrants to purchase up to an aggregate of 275,000 shares of Common Stock for aggregate gross proceeds of $ 495 and (iii) Savbo an aggregate of 50,000 shares of Common stock and PIPE Warrants to purchase up to an aggregate of 50,000 shares of Common Stock for aggregate gross proceeds of $ 90 .

On August 18, 2025, the Company entered into the Series B Purchase Agreement with the Series B Purchasers, including V4, pursuant to which, the Company issued and sold in a private placement an aggregate of (i) 4,500 shares of the Company’s Series B Preferred Stock initially convertible into up to 3,000,000 shares of Common Stock, at an initial conversion price of $ 1.50 per share, and (ii) accompanying Series B Warrants to purchase up to 3,000,000 shares of Common Stock, with an initial exercise price of $ 1.50 per share.

Pursuant to the Series B Private Placement, the Company sold to V4 1,000 shares of Series B Preferred Stock and 666,667 Series B Warrants for aggregate gross proceeds of $ 100 .

Scot Cohen, the Company's Executive Chairman and Chief Executive Officer, holds directly and through V4 Global LLC ("V4"), an entity he controls, shares of Series A Preferred Stock and related warrants.

For the three months ended March 31, 2026, Mr.

Cohen earned dividends totaling $ 91 o n his Series A Preferred Stock.

Series B Preferred Stock

In the private placement of Series B Preferred Stock completed August 18, 2025, V4 purchased 1,000 shares of Series B Preferred Stock and 666,667 Series B Warrants for gross proceeds of $ 1,000 .

PIPE Warrants

In the February 2025 private placement, V4 purchased 1,100,000 shares of Common Stock and 1,100,000 PIPE Warrants for gross proceeds of $ 1,980 ;

Continuum Ventures, LLC (controlled by Jared Novick, President and Chief Operating Officer) purchased 275,000 shares of Common Stock and 275,000 PIPE Warrants for gross proceeds of $ 495 ;

and Savbo Investments LLC (controlled by Marc Savas, a Board member) purchased 50,000 shares of Common Stock and 50,000 PIPE Warrants for gross proceeds of $ 90 .

In the February 2026 private placement, V4

purchased 475,000 shares of Common Stock and 475,000 February 2026 Common

Warrants for gross proceeds of $ 950 ;

Savbo Investments LLC purchased 25,000

shares of Common Stock and 25,000 February 2026 Common Warrants for gross

proceeds of $ 50 ;

and Juggernaut Management, LLC (controlled by John Shulman, a

Board member) purchased 250,000 shares of Common Stock and 250,000 February

2026 Common Warrants for gross proceeds of $ 500 .

License Agreement

The Company is party to a royalty license with Syzygy, a company owned by Elwood G.

Norris, a 5 % or greater stockholder, and James A.

Barnes, a stockholder.

MAJOR CUSTOMERS AND RELATED INFORMATION

For the three months ended September 30, 2025, revenue from one customer accounted for approximately 93 % of revenue, with no other single customer accounting for more than 10% of total revenue.

For the three months ended September 30, 2024, revenue from one distributor accounted for approximately 20 % with no other single customer accounting for more than 10 % of total revenue.

For the nine months ended September 30, 2025, revenue from three distributors accounted for approximately 42 %, 11 %, and 10 % of revenue, respectively, with no other single customer accounting for more than 10% of total revenue.

For the nine months ended September 30, 2024, revenue from two distributors accounted for approximately 28 % and 17 % of revenue, respectively, with no other single customer accounting for more than 10 % of total revenue.

At September 30, 2025, accounts receivable from one customer accounted for 76 %,

of net accounts receivable with no other single customer accounting for more than 10 % of the accounts receivable balance.

At December 31, 2024, accounts receivable from two distributors accounted for 11 % and 10 %, respectively, of net accounts receivable with no other single customer accounting for more than 10 % of the accounts receivable balance.

For the three months ended March 31, 2026, revenue from one customer accounted for approximatel y 40 % of revenue, with no other single customer accounting for more than 10% of total revenue.

For the three months ended March 31, 2025, revenue from three customers accounted for approximately 13 %, 13 % and 11 % of revenue, respectively.

At March 31, 2026, accounts receivable from three distributors accounted for 29 %, 24 %, and 14 % of net accounts receivable and contract assets with no other single customer accounting for more than 10% of the accounts receivable and contract assets balance.

At December 31, 2025, accounts receivable from two distributors accounted for 71 % and 10 %, respectively of net accounts receivable and contract assets, with no other single customer accounting for more than 10% of the accounts receivable and contract assets balance.

The following table summarizes revenue by geographic region.

Revenue is attributed to countries based on customer’s delivery location:

SCHEDULE OF DISAGGREGATION OF REVENUE

For the Three Months For the Nine Months

Ended September 30, Ended September 30,

2025 2024 2025 2024

Three Months Ended March 31,

Americas $ 645 $ 651

Europe, Middle East and Africa 466 114

Asia Pacific 21 1 21 8

Total revenues $ 1,111 $ 765

W1 ACQUISITION

On February 18, 2025, the Company and W1, entered into an Asset Purchase Agreement, dated as of February 18, 2025 pursuant to which, subject to the terms and conditions set forth therein, the Company agreed to acquire substantially all the assets of W1 used in, held for use in or relating to the business of advisory and investigative professional services which related to specific identified customer contracts.

The Company recorded the transaction as an Asset Acquisition in accordance with ASC 805 and recorded $ 54 as intangible assets included in Customer Relationships (See Note 6 “Intangible Assets” above).

The Company has preliminarily assigned a three-year life to such Customer Relationships.

The Company acquired W1 Global to integrate technology enablement into its core offerings and expand into managed technology services supporting the BolaWrap go-to-market strategy.

Following a third-quarter evaluation, the company determined that W1’s investigative services were not essential to Wrap’s domestic or international expansion;

however, customers strongly valued managed services related to policy and training.

As a result, Wrap will continue focusing on managed services in policy governance and training to advance the next era of non-lethal technology development, delivering an integrated response package that combines technology with the support, policy alignment, and governance needed for adoption at the state and federal levels.

SCHEDULE OF DISAGGREGATION OF REVENUE

SUBSEQUENT EVENTS

Mutual Separation with Jerry Ratigan and Appointment of Scot Cohen

On October 21, 2025, the Company and Jerry Ratigan, who served as the Company’s Chief Financial Officer, Principal Accounting Officer and Principal Financial Officer, mutually agreed to the separation of Mr.

Ratigan from such roles, effective as of October 24, 2025.

The terms of Mr.

Ratigan’s separation from the Company have been memorialized pursuant to a General Release and Severance Agreement, dated as of October 21, 2025, which was executed by the Company and Mr.

Ratigan on October 24, 2025 (the “Separation Agreement”).

Pursuant to the Separation Agreement, Mr.

Ratigan is entitled to receive a severance payment in an amount equal to $ 50,000 , representing three months of Mr.

Ratigan’s base salary, less all lawful and authorized withholdings and deductions, payable in a lump sum on the Company’s first regular pay date following the Effective Date (as defined in the Separation Agreement).

In exchange for the consideration provided to Mr.

Ratigan in the Separation Agreement, Mr.

Ratigan agreed to waive and release any claims in connection with Mr.

Ratigan’s employment and separation from the Company.

On October 25, 2025, the board of directors of the Company appointed Scot Cohen, who serves as the Company’s Chief Executive Officer and Principal Executive Officer, to the position of Chief Executive Officer, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer, effective immediately.

Appointment of John Shulman to the Board of Directors

On October 25, 2025, the Board increased the size of the Board to six ( 6 ) members and appointed John Shulman to serve as a member of the Company’s Board, to serve until the Company’s next annual meeting of stockholders or until his successor is duly elected and qualified.

Shulman will be entitled to the standard compensation paid by the Company to all its nonemployee directors under the Company’s director compensation program.

The Company has reviewed activities through May 13, 2026, the date on which this Quarterly Report on Form 10-Q was filed with the Securities and Exchange Commission, and has determined there are no subsequent events requiring disclosure in accordance with ASC 855-10-25-1.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 1. Financial Statements